age-related macular degeneration
Conditions
Interventions
treatment with Eylea
Sponsors
Keio University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Willingness to provide written informed consent 2)AMD with Subfoveal lesion on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography 3)AMD eyes which had not been treated with PDT and/or anti-VEGF 4)baseline BCVA in the study eye over 0.5
Exclusion criteria
Exclusion criteria: 1)Prior treatment with triamcinolone (<3 montsh 2)Prior treatment with dexamethasone <30 days) 3)Prior intraocular surgery (<3 months) 4)Prior vitrectomy 5)Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 6)Patient with pregnancy or its possibility, and with breast-feeding 7)Patient who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with less exudative changes on optical coherence tomography(OCT) at month 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| Results of visual acuity, OCT, angiography, and QOL research | — |
Countries
Japan
Contacts
Public ContactYoko Ozawa
Keio University, School of Medicine Department of Ophthalmology
Outcome results
None listed